This question arises frequently among patients prescribed glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for type 2 diabetes or weight management
In this context, ferroptosis acts as a detrimental mechanism, contributing to tissue degeneration and vessel rupture
Metformin is usually the drug of choice based on costs, safety profile, and long-term efficacy
By reprogramming certain brain receptors, Semaglutide enhances feelings of satiation and reduces cravings, resulting in weight loss
2 Over the last six months, the FDA has dispatched thousands of letters to pharmaceutical and telehealth companies, a volume that exceeds the total sent over the preceding decade
Common reasons include concerns about side effects, cost, medication access, and a preference for gradual changes